Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. 2001

J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
College of Pharmacy, Oregon State University, Corvallis, Oregon 97331-3507, USA.

Plasma concentration time curves following intravenous (i.v.) administration of 1.5 mg/kg of ranitidine, 0.2 mg/kg, 0.4 mg/kg and 0.8 mg/kg of omeprazole, respectively, were analysed in six llamas. Plasma profiles after i.v. administration of both drugs showed plasma concentrations declining in a biexponential manner with a rapid distribution phase. Pharmacokinetics parameters after ranitidine administration to six llamas showed a mean elimination half-life of 1.53 +/- 0.26 h. The mean volume of distribution (Vdss) in llamas was 1.77 +/- 0.31 L/kg, and mean body clearance in llamas was 0.778 +/- 0.109 L/kg/h. Ranitidine produced only a small transitory (<1 h) decline in acid production when administered i.v. at a dose of 1.5 mg/kg. Omeprazole showed dose-dependent nonlinear pharmacokinetics. The mean half-life of 0.2 mg/kg i.v. omeprazole was shorter than that of 0.4 and 0.8 mg/kg i.v. omeprazole, i.e. 0.61, 0.72 and 1.07 h, respectively. The area under the curve (AUC) and mean residence time (MRT) increased with increasing dose, while clearance decreased as dose increased. The decline in acid production following 0.2 mg/kg i.v. omeprazole was highly variable and did not produce a clinically useful suppression of third compartment acid production. In contrast, both 0.4 mg/kg and 0.8 mg/kg omeprazole i.v. administration significantly reduced third compartment acid production. The reduction in acid production following 0.8 mg/kg omeprazole was not significantly greater than the reduction observed following 0.4 mg/kg dosage. Misoprostol (10 microg/kg) was administered i.v. in an absolute alcohol solution. Two animals collapsed following drug administration. While the side-effects could have been produced by either misoprostol or the alcohol vehicle, the clinical changes were more consistent with an adverse drug reaction. Unfortunately, the limitation of UV detection did not provide the sensitivity needed to quantify the amount of misoprostol in llama plasma, and the pharmacokinetics could not be evaluated.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D002161 Camelids, New World Camelidae of the Americas. The extant species are those originating from South America and include alpacas, llamas, guanicos, and vicunas. Alpacas,Guanacos,Llamas,Lama glama,Lama glama guanicoe,Lama guanicoe,Lama pacos,Vicugna pacos,Vicugna vicugna,Vicunas,Alpaca,Camelid, New World,Guanaco,Llama,New World Camelid,New World Camelids,Vicuna
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005745 Gastric Acidity Determination Gastric analysis for determination of free acid or total acid. Acidity Determination, Gastric,Acidity Determinations, Gastric,Determination, Gastric Acidity,Determinations, Gastric Acidity,Gastric Acidity Determinations
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer

Related Publications

J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
January 1999, The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia,
J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
December 2009, Infectious disease clinics of North America,
J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
June 1992, Critical care nursing clinics of North America,
J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
January 2004, Clinical pharmacokinetics,
J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
November 1998, Mayo Clinic proceedings,
J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
March 2019, Nitric oxide : biology and chemistry,
J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
August 1987, Clinical pharmacokinetics,
J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
December 2013, Clinical pharmacokinetics,
J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
April 2002, The Annals of pharmacotherapy,
J M Christensen, and T Limsakun, and B B Smith, and N Hollingshead, and M Huber
February 2021, Surgical infections,
Copied contents to your clipboard!